Characterization of the neuropsychological phenotype of glycine N-methyltransferase-/- mice and evaluation of its responses to clozapine and sarcosine treatments

European Neuropsychopharmacology

Volumn 22, Issue 8, 2012, Pages 596-606

  Yang, Ching Ping ^a   Wang, Hsiang An ^a   Tsai, Tung Hu ^a   Fan, Angela ^a   Hsu, Chia Lang ^a   Chen, Chun Jung ^b   Hong, Chen Jee ^a,c   Chen, Yi Ming Arthur ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Endophenotype; Glycine N methyltransferase; Knockout mice; Prepulse inhibition; Sarcosine; Schizophrenia

Indexed keywords

CLOZAPINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLYCINE METHYLTRANSFERASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B BETA; PROTEIN S6; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; SARCOSINE;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; DRUG MECHANISM; ENZYME MECHANISM; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MOUSE; NEUROPSYCHOLOGY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLYCINE N-METHYLTRANSFERASE; HUMANS; MALE; METENCEPHALON; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; ORGAN SPECIFICITY; RNA, MESSENGER; SARCOSINE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84864529944     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.12.007     Document Type: Article

References (60)

1. Bergeron F., Otto A., Blache P., Day R., Denoroy L., Brandsch R., Bataille D. Molecular cloning and tissue distribution of rat sarcosine dehydrogenase. Eur. J. Biochem. 1998, 257:556-561.
2. Bjarnadottir M., Misner D.L., Haverfield-Gross S., Bruun S., Helgason V.G., Stefansson H., Sigmundsson A., Firth D.R., Nielsen B., Stefansdottir R., Novak T.J., Stefansson K., Gurney M.E., Andresson T. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. J. Neurosci. 2007, 27:4519-4529.
3. Black M.D., Varty G.B., Arad M., Barak S., De Levie A., Boulay D., Pichat P., Griebel G., Weiner I. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl.) 2009, 202:385-396.
4. Blumenstein J., Williams G.R. The enzymic N-methylation of glycine. Biochem. Biophys. Res. Commun. 1960, 3:259-263.
5. Bork P., Ouzounis C., Sander C., Scharf M., Schneider R., Sonnhammer E. Comprehensive sequence analysis of the 182 predicted open reading frames of yeast chromosome III. Protein Sci. 1992, 1:1677-1690.
6. Boulay D., Bergis O., Avenet P., Griebel G. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 2010, 35:416-427.
7. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 1990, 47:181-188.
8. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl.) 2001, 156:234-258.
9. Bullock A.E., Slobe B.S., Vazquez V., Collins A.C. Inbred mouse strains differ in the regulation of startle and prepulse inhibition of the startle response. Behav. Neurosci. 1997, 111:1353-1360.
10. Butterworth R.F. Hepatic encephalopathy. Alcohol Res. Health 2003, 27:240-246.
11. Chen Y.M., Chen L.Y., Wong F.H., Lee C.M., Chang T.J., Yang-Feng T.L. Genomic structure, expression, and chromosomal localization of the human glycine N-methyltransferase gene. Genomics 2000, 66:43-47.
12. Chen Y.J., Johnson M.A., Lieberman M.D., Goodchild R.E., Schobel S., Lewandowski N., Rosoklija G., Liu R.C., Gingrich J.A., Small S., Moore H., Dwork A.J., Talmage D.A., Role L.W. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J. Neurosci. 2008, 28:6872-6883.
13. Cook R.J., Wagner C. Glycine N-methyltransferase is a folate binding protein of rat liver cytosol. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:3631-3634.
14. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26:365-384.
15. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 29:571-625.
16. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
17. Feng J., Zhou Y., Campbell S.L., Le T., Li E., Sweatt J.D., Silva A.J., Fan G. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat. Neurosci. 2010, 13:423-430.
18. Freedman R. Schizophrenia. N. Engl. J. Med. 2003, 349:1738-1749.
19. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
20. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., Bakshi K., Kamins J., Borgmann-Winter K.E., Siegel S.J., Gallop R.J., Arnold S.E. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 2006, 12:824-828.
21. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry 2006, 60:132-140.
22. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
23. Hong L.E., Wonodi I., Stine O.C., Mitchell B.D., Thaker G.K. Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol. Psychiatry 2008, 63:17-23.
24. Huang Y.Z., Won S., Ali D.W., Wang Q., Tanowitz M., Du Q.S., Pelkey K.A., Yang D.J., Xiong W.C., Salter M.W., Mei L. Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. Neuron 2000, 26:443-455.
25. Huang Y.C., Lee C.M., Chen M., Chung M.Y., Chang Y.H., Huang W.J., Ho D.M., Pan C.C., Wu T.T., Yang S., Lin M.W., Hsieh J.T., Chen Y.M. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin. Cancer Res. 2007, 13:1412-1420.
26. Jones C.A., Watson D.J., Fone K. Animal models of schizophrenia. Br. J. Pharmacol 2011, 164:1162-1194.
27. Karam C.S., Ballon J.S., Bivens N.M., Freyberg Z., Girgis R.R., Lizardi-Ortiz J.E., Markx S., Lieberman J.A., Javitch J.A. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol. Sci. 2010, 31:381-390.
28. Kerr S.J. Competing methyltransferase systems. J. Biol. Chem. 1972, 247:4248-4252.
29. Lai M.C., Yang D.R., Chuang M.J. Regulatory factors associated with synthesis of the osmolyte glycine betaine in the halophilic methanoarchaeon Methanohalophilus portucalensis. Appl. Environ. Microbiol. 1999, 65:828-833.
30. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., Tsai G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2005, 62:1196-1204.
31. Lane H.Y., Huang C.L., Wu P.L., Liu Y.C., Chang Y.C., Lin P.Y., Chen P.W., Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 2006, 60:645-649.
32. Lane H.Y., Lin C.H., Huang Y.J., Liao C.H., Chang Y.C., Tsai G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 2010, 13:451-460.
33. LaPlant Q., Vialou V., Covington H.E., Dumitriu D., Feng J., Warren B.L., Maze I., Dietz D.M., Watts E.L., Iniguez S.D., Koo J.W., Mouzon E., Renthal W., Hollis F., Wang H., Noonan M.A., Ren Y., Eisch A.J., Bolanos C.A., Kabbaj M., Xiao G., Neve R.L., Hurd Y.L., Oosting R.S., Fan G., Morrison J.H., Nestler E.J. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat. Neurosci. 2010, 13:1137-1143.
34. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28:325-334.
35. Liao Y.J., Liu S.P., Lee C.M., Yen C.H., Chuang P.C., Chen C.Y., Tsai T.F., Huang S.F., Lee Y.H., Chen Y.M. Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: implications of the gender disparity in liver cancer susceptibility. Int. J. Cancer 2009, 124:816-826.
36. Liu S.P., Li Y.S., Chen Y.J., Chiang E.P., Li A.F., Lee Y.H., Tsai T.F., Hsiao M., Huang S.F., Chen Y.M. Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in the liver. Hepatology 2007, 46:1413-1425.
37. Liu Y., Xu F., Zeng X., Yang L., Deng Y., Wu Z., Feng Y., Li X. Application of a liquid chromatography/tandem mass spectrometry method to pharmacokinetic study of mangiferin in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878:3345-3350.
38. Magen I., Avraham Y., Ackerman Z., Vorobiev L., Mechoulam R., Berry E.M. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J. Hepatol. 2009, 51:528-534.
39. Martinez-Chantar M.L., Vazquez-Chantada M., Ariz U., Martinez N., Varela M., Luka Z., Capdevila A., Rodriguez J., Aransay A.M., Matthiesen R., Yang H., Calvisi D.F., Esteller M., Fraga M., Lu S.C., Wagner C., Mato J.M. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 2008, 47:1191-1199.
40. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
41. Michitaka K., Tokumoto Y., Uesugi K., Kisaka Y., Hirooka M., Konishi I., Mashiba T., Abe M., Hiasa Y., Matsuura B., Horiike N., Shoda T., Onji M. Neuropsychiatric dysfunction in patients with chronic hepatitis and liver cirrhosis. Hepatol. Res. 2008, 38:1069-1075.
42. Need A.C., Ge D., Weale M.E., Maia J., Feng S., Heinzen E.L., Shianna K.V., Yoon W., Kasperaviciute D., Gennarelli M., Strittmatter W.J., Bonvicini C., Rossi G., Jayathilake K., Cola P.A., McEvoy J.P., Keefe R.S., Fisher E.M., St Jean P.L., Giegling I., Hartmann A.M., Moller H.J., Ruppert A., Fraser G., Crombie C., Middleton L.T., St Clair D., Roses A.D., Muglia P., Francks C., Rujescu D., Meltzer H.Y., Goldstein D.B. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet. 2009, 5:e1000373.
43. Ogawa H., Gomi T., Fujioka M. Mammalian glycine N-methyltransferases. Comparative kinetic and structural properties of the enzymes from human, rat, rabbit and pig livers. Comp. Biochem. Physiol. B 1993, 106:601-611.
44. Paylor R., Crawley J.N. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl.) 1997, 132:169-180.
45. Sei Y., Ren-Patterson R., Li Z., Tunbridge E.M., Egan M.F., Kolachana B.S., Weinberger D.R. Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms. Mol. Psychiatry 2007, 12:946-957.
46. Seshadri S., Kamiya A., Yokota Y., Prikulis I., Kano S., Hayashi-Takagi A., Stanco A., Eom T.Y., Rao S., Ishizuka K., Wong P., Korth C., Anton E.S., Sawa A. Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5622-5627.
47. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl.) 1985, 85:367-370.
48. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 2003, 60:1187-1192.
49. Swerdlow N.R., Paulsen J., Braff D.L., Butters N., Geyer M.A., Swenson M.R. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J. Neurol. Neurosurg. Psychiatry 1995, 58:192-200.
50. Thiselton D.L., Vladimirov V.I., Kuo P.H., McClay J., Wormley B., Fanous A., O'Neill F.A., Walsh D., Van den Oord E.J., Kendler K.S., Riley B.P. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol. Psychiatry 2008, 63:449-457.
51. Tsai G., Lane H.Y., Yang P., Chong M.Y., Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 2004, 55:452-456.
52. Tseng T.L., Shih Y.P., Huang Y.C., Wang C.K., Chen P.H., Chang J.G., Yeh K.T., Chen Y.M., Buetow K.H. Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer. Cancer Res. 2003, 63:647-654.
53. Wang Q., Liu L., Pei L., Ju W., Ahmadian G., Lu J., Wang Y., Liu F., Wang Y.T. Control of synaptic strength, a novel function of Akt. Neuron 2003, 38:915-928.
54. Wang X., Li W., Parra J.L., Beugnet A., Proud C.G. The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol. Cell. Biol. 2003, 23:1546-1557.
55. Willott J.F., Tanner L., O'Steen J., Johnson K.R., Bogue M.A., Gagnon L. Acoustic startle and prepulse inhibition in 40 inbred strains of mice. Behav. Neurosci. 2003, 117:716-727.
56. Yang S.Y., Hong C.J., Huang Y.H., Tsai S.J. The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats. Neurosci. Lett. 2010, 469:127-130.
57. Yen, C.H., Lu, Y.C., Li, Y.C., Lee, M.C., Chen, C.Y., Cheng, M.Y., Hung, S.F., Chen, K.F., Cheng, A.L., Liao, L.Y., Lee, Y.H., Chen, Y.M., in press. Functional Characterization of GNMT and its Interacting Protein-DEPTOR in Hepatocellular Carcinoma. Mol. Med. (Electronic publication ahead of print). doi:. doi:10.2119/molmed.2011.00331.
58. Yeo E.J., Wagner C. Tissue distribution of glycine N-methyltransferase, a major folate-binding protein of liver. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:210-214.
59. Yoon S.C., Seo M.S., Kim S.H., Jeon W.J., Ahn Y.M., Kang U.G., Kim Y.S. The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex. Neurosci. Lett. 2008, 434:23-28.
60. Yoshii A., Constantine-Paton M. BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nat. Neurosci. 2007, 10:702-711.